Matinas Biopharma | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.4.

EBIT: As of FY2025 Q3, the actual value is USD -1.577 M.

Segment Revenue

• The company did not report any revenue for the three and nine months ended September 30, 2025 and 2024, as it is still in the clinical stage of development.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was $1,532,000, compared to $4,275,000 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $8,433,000, compared to $15,818,000 in 2024.
• Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $1,577,000, down from $4,381,000 in 2024. For the nine months ended September 30, 2025, operating expenses were $5,360,000, compared to $16,124,000 in 2024.
• Research and Development Expenses: R&D expenses were $0 for the three months ended September 30, 2025, compared to $2,239,000 in 2024. For the nine months ended September 30, 2025, R&D expenses were $85,000, compared to $9,057,000 in 2024.
• General and Administrative Expenses: G&A expenses for the three months ended September 30, 2025, were $1,577,000, down from $2,142,000 in 2024. For the nine months ended September 30, 2025, G&A expenses were $5,275,000, compared to $7,067,000 in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $5,502,000 for the nine months ended September 30, 2025, compared to $12,375,000 in 2024.
• Investing Cash Flow: Net cash provided by investing activities was $320,000 for the nine months ended September 30, 2025, compared to $8,708,000 in 2024.
• Financing Cash Flow: Net cash provided by financing activities was $3,333,000 for the nine months ended September 30, 2025, compared to $9,175,000 in 2024.

Unique Metrics

• Warrant Liability: A loss of $3,161,000 was recognized for the nine months ended September 30, 2025, due to changes in the fair value of the warrant liability.

Future Outlook and Strategy

• Core Business Focus: The company aims to secure partners to monetize MAT2203 and raise additional non-dilutive capital through licensing or sale. They plan to advance MAT2203 into Phase 3 development and conserve cash while evaluating strategic options, including in-licensing assets or seeking a merger partner.
• Non-Core Business: The company is exploring strategic options, including potential mergers or acquisitions, to enhance its business prospects.